Literature DB >> 28228434

Sagittal sinus thrombosis in JAK2-V617F mutation without overt myeloproliferative disorder.

Prashant Ramesh Bhand1, Supriya Ramesh Karde1, Nagabathula Ramesh2.   

Abstract

We describe a case of a man aged 41 years who presented with a history of generalised headaches for 1 week and an acute episode of tonic-clonic seizures. He had no history of medical illness, was non-smoker, with an extensive family history of haematological disorders. Initial CT brain with contrast did not show any abnormalities in brain parenchyma. X-ray and CT right shoulder showed shoulder dislocation secondary to trauma associated with seizure prior to hospital admission. Subsequently, MRA and MRV brain was arranged, which revealed extensive expansible occlusive filling defect dominating the middle of superior sagittal sinus with left frontal cortical and subcortical acute oedema. He was promptly started on anticoagulation therapy. Considering the unusual site and unprovoked nature of thrombosis, further investigations including JAK2 mutation were arranged which revealed latent myeloproliferative disorder. He was referred to haematology services for further follow-up and monitoring of latent myeloproliferative disorder. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28228434      PMCID: PMC5337645          DOI: 10.1136/bcr-2016-218298

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

Review 1.  Cerebral venous thrombosis: diagnosis and management.

Authors:  M G Bousser
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

Review 2.  Cerebral venous thrombosis: an update.

Authors:  Marie-Germaine Bousser; José M Ferro
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

Review 3.  Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

Authors:  R Landolfi; L Di Gennaro; A Falanga
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

4.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

Review 5.  JAK2V617F mutation in patients with thrombosis: to screen or not to screen?

Authors:  S G Xavier; T Gadelha; S M Rezende; I R Zalcberg; N Spector
Journal:  Int J Lab Hematol       Date:  2010-12-01       Impact factor: 2.877

Review 6.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.

Authors:  Jasper H Smalberg; Lidia R Arends; Dominique C Valla; Jean-Jacques Kiladjian; Harry L A Janssen; Frank W G Leebeek
Journal:  Blood       Date:  2012-10-04       Impact factor: 22.113

Review 7.  Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.

Authors:  A Casini; P Fontana; T P Lecompte
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

8.  Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

Authors:  Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán; Juan Carlos Reverter; Neus Villamor; Dolors Colomer; Francisco Cervantes
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

9.  Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.

Authors:  Stephanie P'ng; Ben Carnley; Ross Baker; Nick Kontorinis; Wendy Cheng
Journal:  Clin Gastroenterol Hepatol       Date:  2008-03-07       Impact factor: 11.382

Review 10.  JAK2 V617F: implications for thrombosis in myeloproliferative diseases.

Authors:  Elizabeth O Hexner
Journal:  Curr Opin Hematol       Date:  2007-09       Impact factor: 3.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.